Michael Lowney, DO
Family Medicine · Boston, MANPI 1801946926
Payments from drug & device makers
Across 181 payments — averaging $21.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$633
- Boehringer Ingelheim$510
- Novo Nordisk$312
- E.r. Squibb & Sons, L.L.C.$220
- Lilly USA, LLC$209
- plus $759 from 18 others
What the payments were for
- Food & beverage$3,916100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 60 | $1,279 |
| AbbVie(2 entities) | 31 | $633 |
| Boehringer Ingelheim | 22 | $510 |
| Novo Nordisk | 16 | $312 |
| E.r. Squibb & Sons, L.L.C. | 9 | $220 |
| Lilly USA, LLC | 9 | $209 |
| GSK | 5 | $125 |
| Pfizer | 6 | $110 |
| Otsuka America Pharmaceutical, Inc. | 4 | $81 |
| Genentech USA, Inc. | 4 | $65 |
| Esperion Therapeutics, Inc. | 1 | $59 |
| GRT US Holding, Inc. | 1 | $49 |
| Bristol Myers Squibb | 2 | $45 |
| Astellas Pharma US Inc | 1 | $33 |
| Exact Sciences | 1 | $25 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $24 |
| Ardelyx, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| Amgen | 1 | $20 |
| Dermira, Inc. | 1 | $15 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Philips North America LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$100
How this compares
$3,922 in reported general payments places this provider in the 90th percentile of 1,049 family medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 43 | $1,431 |
| Celecoxib | 16 | $892 |
| Fenofibrate | 31 | $884 |
| Omeprazole | 39 | $852 |
| Lisinopril | 78 | $677 |
| Rosuvastatin Calcium | 22 | $656 |
| Tamsulosin Hcl | 33 | $558 |
| Metoprolol Succinate | 29 | $483 |
| Gabapentin | 26 | $440 |
| Escitalopram Oxalate | 30 | $372 |
| Montelukast Sodium | 33 | $349 |
| Simvastatin | 55 | $333 |
| Verapamil ErVerapamil Hcl | 12 | $259 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 24 | $234 |
| Amlodipine Besylate | 48 | $227 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Boston
- Katherine Gergen BarnettBoston$226K
- Peter O'DwyerBoston$163K
- Larry CulpepperBoston$109K
- Suzanne MitchellBoston$69K
- Michael LowneyBoston$13K
- Renee CrichlowBoston$5K
- Robert BeckWestford$2.1M
- Kelly LannuttiWeymouth$122K
- Jennifer WeylerWorcester$105K
- Megan McCoyFramingham$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.